Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of IBI306 in Healthy Subjects

Next Previous
Trial Profile

A Randomized, Double Blind, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of IBI306 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tafolecimab (Primary) ; Tafolecimab (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions
  • Sponsors Innovent Biologics

    • Most Recent Events

    • 01 Sep 2020 Results assessing safety and efficacy from two studies: phase 1 single ascending does study (n=58) and phase 2 multiple ascending dose study presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
    • 30 Aug 2020 According to an Innovent Biologics media release, Professor Yimin Cui, director of the clinical trial center and the director the Institute of Pharmacology in Peking University First Hospital is also the leading PI of this study (CIBI306A101).
    • 30 Aug 2020 According to an Innovent Biologics media release, this study results were successfully presented in the 2020 European Society of Cardiology (ESC) annual conference (August 29 to September 1, Central European Summer Time) as e-Poster.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top